Jade Biosciences (JBIO) Return on Capital Employed (2021 - 2026)
Jade Biosciences (JBIO) reported Return on Capital Employed of 42.78% for Q1 2026, up 2431.0% on a YoY basis from 1.69% in Q1 2025, and up 2.2% quarter-over-quarter from 43.74% in Q4 2025.
Jade Biosciences (JBIO) Return on Capital Employed (2021 - 2026) Analysis & Trends
Jade Biosciences has reported Return on Capital Employed for 6 years, with the latest figure at 42.78% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 2431.0% year-over-year to 42.78%; the trailing twelve-month figure through Mar 2026 stood at 42.78% (up 2431.0% YoY), and the FY2025 full-year result was 58.3%, down 4173.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 42.78%, up from 43.74% in the prior quarter.
- The five-year high for Return on Capital Employed was 3.67% in Q3 2024, with the low at 71.6% in Q4 2024.
- Historically, Return on Capital Employed has averaged 29.88% across 5 years, with a median of 23.92% in 2022.
- The largest YoY upside for Return on Capital Employed was 2821 bps in 2024 against a maximum downside of 5802 bps in 2024.
- Jade Biosciences' Return on Capital Employed stood at 8.1% in 2022, then slumped by 68 bps to 13.59% in 2023, then plunged by 427 bps to 71.6% in 2024, then soared by 39 bps to 43.74% in 2025, then climbed by 2 bps to 42.78% in 2026.
- The last three Return on Capital Employed figures came in at 42.78% (Q1 2026), 43.74% (Q4 2025), and 46.33% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Jade Biosciences | 973.55 Mn | 973.55 Mn | - | -42.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.78% |
| Dec 31, 2025 | -43.74% |
| Sep 30, 2025 | -46.33% |
| Jun 30, 2025 | -58.85% |
| Mar 31, 2025 | -67.09% |
| Dec 31, 2024 | -71.60% |
| Sep 30, 2024 | 3.67% |
| Jun 30, 2024 | -3.32% |
| Mar 31, 2024 | -22.45% |
| Dec 31, 2023 | -13.59% |
| Sep 30, 2023 | -24.54% |
| Jun 30, 2023 | -20.17% |
| Mar 31, 2023 | -14.64% |
| Dec 31, 2022 | -8.10% |
| Sep 30, 2022 | -31.71% |
| Jun 30, 2022 | -23.92% |
| Mar 31, 2022 | -18.78% |
| Dec 31, 2021 | -12.99% |
| Sep 30, 2021 | -15.42% |